To obtain such high numbers of PBMCs these B-NHL patients underwent leukapheresis as a part of approved clinical trial with CD19 CAR-T cells and all of them had relapsed/refractory B-cell acute leukemia or B-cell lymphoma with more than 3 lines of therapies. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.